TY - JOUR ID - 31355 TI - A Pooled Study on Combination of Gemcitabine and Nedaplatin for Treating Patients with Non-small Cell Lung Cancer JO - Asian Pacific Journal of Cancer Prevention JA - APJCP LA - en SN - 1513-7368 Y1 - 2015 PY - 2015 VL - 16 IS - 14 SP - 5963 EP - 5966 KW - Gemcitabine and nedaplatin KW - non-small cell lung cancer DO - N2 - Background: This analysis was conducted to evaluate the efficacy and safety of a combination of gemcitabineand nedaplatin in treating patients with non-small cell lung cancer. Methods: Clinical studies evaluating theefficacy and safety of a combination of gemcitabine and nedaplatin with attention to response and safety forpatients with non-small cell lung cancer were identified using a predefined search strategy. Pooled responserates for gemcitabine and nedaplatin were calculated. Results: In gemcitabine and nedaplatin based regimens, 4clinical studies including 112 patients with non-small cell lung cancer were considered eligible for inclusion. Thepooled analysis suggested that the pooled reponse rate was 40.2% (45/112). Main side effects included grade 3-4neutropenia, thrombocytopenia, and anemia. Grade 3-4 nonhematological toxicity included nausea and vomiting,diarrhea, and hepatic dysfunction. There were no treatment-related deaths. Conclusion: This evidence basedanalysis suggests that the combination of gemcitabine and nedaplatin is associated with good response rate andaccepted toxicity for treating patients with non-small cell lung cancer. UR - https://journal.waocp.org/article_31355.html L1 - https://journal.waocp.org/article_31355_5af1f26a7c12f9659e11d4baba76506a.pdf ER -